Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Maryam Bainazar"'
Autor:
James S. Blachly, Ann-Kathrin Eisfeld, Sophia E. Maharry, Christopher J. Walker, Gonzalo N. Olaverria Salavaggione, Maryam Bainazar, Albert de la Chapelle, Kelly Regan, Megan C. Duggan, Madison Krischak, Susheela Tridandapani, William E. Carson, Nicholas Latchana, Andrew Stiff
Publikováno v:
Proceedings of the National Academy of Sciences. 114:9629-9634
Activating mutations in BRAF are found in 50% of melanomas and although treatment with BRAF inhibitors (BRAFi) is effective, resistance often develops. We now show that recently discovered NRAS isoform 2 is up-regulated in the setting of BRAF inhibit
Autor:
Kevin W. Hoag, Ramiro Garzon, Sophia E. Maharry, Christopher J. Walker, Sujay Mehta, Mitra Patel, Denis C. Guttridge, Ann-Kathrin Eisfeld, Xiaomeng Huang, Sandya Liyanarachchi, Albert de la Chapelle, James S. Blachly, Maryam Bainazar, Malori A. Lankenau, Clara D. Bloomfield, Parvathi Ranganathan
Publikováno v:
Cancer Discovery. 6:1036-1051
Chromosomal aberrations and multiple genome-wide association studies (GWAS) have established a major hematopoietic quantitative trait locus in chromosome 6q23.3. The locus comprises an active enhancer region, in which some of the associated SNPs alte
Autor:
Eunice S. Wang, Luke K Genutis, Ralf Bundschuh, Clara D. Bloomfield, Richard Stone, A de la Chapelle, Jessica Kohlschmidt, Christopher J. Walker, Jonathan E. Kolitz, Bayard L. Powell, Andrew J. Carroll, A-K Eisfeld, Maryam Bainazar, Krzysztof Mrózek
Publikováno v:
Leukemia
Autor:
Jonathan E. Kolitz, Jessica Kohlschmidt, Christopher J. Walker, A-K Eisfeld, Richard Stone, Maria R. Baer, Shelley Orwick, James S. Blachly, John C. Byrd, A de la Chapelle, Deedra Nicolet, Clara D. Bloomfield, Maryam Bainazar, Karl Kroll, Andrew J. Carroll, Chandni Shah, Sebastian Schwind, Bayard L. Powell, Krzysztof Mrózek
Publikováno v:
Leukemia. 31(6)
Core-binding factor acute myeloid leukemia (CBF-AML) is defined by the presence of either t(8;21)(q22;q22)/RUNX1-RUNX1T1 or inv(16)(p13.1q22)/t(16;16)(p13.1;q22)/CBFB-MYH11. The resulting fusion genes require a “second hit” to initiate leukemogen
Autor:
Andrew J. Carroll, Chandni Shah, Maria R. Baer, Sebastian Schwind, Krzysztof Mrózek, Christopher J. Walker, Ann-Kathrin Eisfeld, James S. Blachly, Maryam Bainazar, Jonathan E. Kolitz, Shelley Orwick, Karl Kroll, Deedra Nicolet, Jessica Kohlschmidt, Richard Stone, Bayard L. Powell, Albert de la Chapelle, Clara D. Bloomfield, John C. Byrd
Publikováno v:
Blood. 128:2740-2740
CBF-AML is defined by the presence of either t(8;21)(q22;q22)/RUNX1-RUNX1T1 or inv(16)(p13.1q22)/t(16;16)(p13.1;q22)/CBFB-MYH11. The resulting fusion genes require a "second hit" to initiate leukemogenesis. Although compared with other AML subtypes p
Autor:
Andrew Stiff, Ann-Kathrin Eisfeld, William E. Carson, Megan C. Duggan, Maryam Bainazar, Nicholas Latchana, Joseph Markowitz, Albert de la Chapelle, Gonzalo N. Olaverria Salavaggione
Publikováno v:
Cancer Research. 76:301-301
Activating mutations in BRAF are found in 50% of melanomas and are associated with poor outcomes due to constitutive activation of the mitogen activated protein kinase (MAPK) pathway. Treatment with BRAF inhibitors (BRAFi), such as vemurafenib, is ef